Background: the diagnosis of dementia, in particular Alzheimer's disease (AD), is enhanced with the use of molecular biomarkers. Since cerebrospinal fluid analysis and molecular neuroimaging are not routinely used in many countries, blood biomarker molecules may be more readily applicable in a routine clinical setting. Methods: twenty-five subjects with a clinical diagnosis of AD and 26 control participants were assessed for cognitive and behavioural functioning. Platelet measures of amyloid protein precursor (APP), tau protein, clusterin, α-synuclein and immunoglobulin (Ig) were measured. Linear regression analysis for platelet proteins and cognitive and behavioural status were determined, and receiver operating characteristic (ROC) curves created to assess the discriminating power of each biochemical parameter between AD and control groups. Results: both AD and control subjects had similar platelet levels of measures platelet proteins, with the exception of slightly elevated Ig levels in AD subjects (P = 0.052). The latter were not related to increasing age, or extent of cognitive impairment. APP-N measures were negatively correlated with cognitive scores. Conclusion: these preliminary findings suggest that platelet measures of the traditional biomarkers for AD are feasible in the periphery. The measures of platelet APP-N and Ig, in particular, merit further study in a larger cohort of AD and control subjects.
The diagnosis of Alzheimer's disease (AD) is based on the application of standardised diagnostic criteria following clinical and neuropsychological assessments. The recently revised NINCDS-ADRDA research criteria for AD [1] and National Institute on Aging (NIA) and Alzheimer's Association guidelines [2] recommend inclusion of at least one or more abnormal biomarkers among structural (MRI) and molecular (PET) neuroimaging, and cerebrospinal fluid (CSF) analysis of amyloid beta (Aβ) or tau proteins as a supportive diagnostic feature. Since these procedures are invasive and not routinely used in many countries, the identification of blood biomarker molecules may be more readily applicable in a routine clinical setting, including primary care.
The identified AD blood/plasma peripheral biomarkers (including those that reflect AD neuropathology, e.g. clusterin and Aβ) have proven to be rather inconsistent and not reproducible [3] [4] [5] [6] . This may be due either to their unclear origin (whether they come from the brain or periphery, e.g. platelets, skeletal muscles, erythrocytes), or to length of sample storage, co-morbidities and pharmacological treatments [7] . However, most recent studies associated the decrease in Aβ42 [3, 4] , increased Aβ40 [4] , and lower Aβ42/ Aβ40 levels with faster cognitive decline and conversion to AD [3, 4] .
Platelets bear similarities to neurons in respect to having similar molecular mechanisms of neuronal exocytosis and containing basic proteins and polypeptides which cause neuronal depolarization [8] . Platelet biochemistry has been used as peripheral marker (including monitoring therapeutic outcomes and progression) in schizophrenia and depression [9] , but is poorly investigated in neurodegenerative diseases. Interestingly, platelets are the primary source of circulating amyloid precursor protein (APP) and Aβ, and altered platelet APP processing appears to have high accuracy in identifying AD [7] . In the current study, we assessed several protein candidates associated with AD pathogenesis in platelets isolated from AD and control subjects with no cognitive impairment, and related them to dementia clinical symptoms.
A total of 51 subjects were recruited over a one-year period (2009-10): 25 fulfilled the NINCDS-ADRDA criteria for probable diagnosis of AD (recruited through the North East DeNDRoN research network), and 26 participants (24 AD spouses and children, and two other volunteers) with no cognitive and/or neurological problems served as a control group (Table 1 ). All subjects underwent comprehensive clinical assessment [10] [11] [12] [13] , including demographic information, clinical history and physical and neurological examination. The research was approved by the North East Research Ethics Committee.
For quantitative assays, platelets were prepared according to a modified protocol [9] , and platelet proteins were measured by indirect ELISA immunoassays, using immunoprobes for APP, clusterin, immunoglobulins (Ig), tau and α-synuclein (Supplementary data are available in Age and Ageing online, Appendix). All values were expressed as relative arbitrary units of immunoreactivity, similar to previous reports [14] . The intra-and inter-assay precisions ranged from 2.24 to 6.25% and 1.01-6.89% for inter and within assay precision, respectively.
Statistical analysis was performed using PASW Statistics 17, Release Version 17.0.2 (©SPSS, Inc., 2009, Chicago, IL, USA): Pearson Chi 2 and ANOVA to analyse the relationships between categorical data (e.g. gender) and test for group differences between continuous variables (e.g. platelet proteins, cognitive and behavioural scales), respectively; regression analysis to determine the predictors of cognitive and behavioural changes, and stepwise regression analysis to identify the best predictors of cognitive function (as measured by CAMCOG and MMSE), with independent variables including: age, gender, diagnosis of AD, cholinesterase inhibitor (ChEI) treatment and platelet measures. ROC curves were created to assess diagnostic accuracy of each biochemical parameter to discriminate AD versus control subjects. Significance of analysis was set at P ≤ 0.05, to provide 95% confidence interval.
The control and dementia groups had similar levels of measured platelet proteins, with the exception of the platelet Ig that was slightly elevated in AD subjects (P = 0.052; Table 1 ). The Ig measure had 84% sensitivity and 42% specificity ( Table 2 No major physical problems were reported in any of the AD participants. However, 2 (8%) were taking thyroid hormone replacement medication, 6 (24%) smaller doses of antidepressants, 11 (44%) antihypertensive medication, 13 (52%) anti-inflammatory drugs (e.g. aspirin) and 9 (36%) cholesterol-lowering medication. These figures are similar to those reported for the general population [28, 29] . Data for the control subjects were not available. control subjects were independent of age and gender (Table 2) . Although the platelet protein levels were similar between the groups, the APP-N platelet levels were negatively related to cognitive scores in all analysed participants and the AD subjects alone (MMSE and CAMCOG scores) ( Table 2 ). These findings were also confirmed in the stepwise regression analysis for the entire group (n = 51 subjects), with platelet levels of APP-N, age and ChEI treatment being the best predictors for cognitive function, as measured by CAMCOG and MMSE. Thus, age accounted for 17.3% of the variation of the CAMCOG scores, and this increased to 32.9 and 39.7% when APP-N measures and ChEI treatment were included, respectively. Similar figures were obtained for the MMSE measures of cognition, with APP-N accounting for 15% of the variation, increasing to 27.6% when age was included. In AD subjects, behavioural and mood changes could not be explained by platelet measures (Table 2) .
These preliminary findings suggest that platelet measures of AD-associated proteins are feasible in the periphery. The measures of platelet Ig and APP-N, in particular, merit further study in a larger cohort of AD and control subjects. The Ig measures include both the alpha-granule IgG (mirroring the concentration and composition of plasma IgG) and platelet surface IgG (that may represent antiplatelet antibodies), thus reflecting the total platelet Ig content. Since alpha-granule IgG compromises almost all of the total platelet IgG content (99% [15] ), the observed platelet differences in AD may correspond to those previously described in proteomic [16] and quantitative studies [17] . Similar to our findings, the elevated plasma levels of IgG and Aβ IgG complexes reported in subjects with mild cognitive impairment (MCI) and AD, were not correlated with cognitive functioning [17] .
The platelet levels of α-synuclein, N-and C-terminal end of APP did not distinguish between AD and control subjects. The similar platelet levels of α-synuclein in AD and control subjects, independent of age and gender, are in agreement with previous findings of total α-synuclein in plasma and brain tissue [18, 19] . Although our APP findings appear to be somewhat different from previous reports on a significantly reduced APP ratio (130 kDa/106-110 kDa; assessing the N-terminal APP end) in subjects with early and advanced AD [7, 20] , they provide further support for the importance of the N-terminal end of the APP molecule in the AD pathogenesis, and its potential clinical relevance in AD cognitive impairment. Furthermore, the increased platelet APP-N measures in the current study were associated with cognitive impairment, similarly to a recent report on increase in platelet mRNA APP in AD subjects [21] .
Although two most recent studies found higher levels of plasma clusterin in MCI [5] and further increase with AD progression [22] , this was not confirmed in presymptomatic AD subjects followed over a 10-year period [23] . The differences in the reported findings in AD, both in platelet (this study), serum [23] and plasma [5, 22] , may either reflect variations in diet and underlying physical problems (e.g. type II diabetes, coronary heart problems and myocardial infarction) among the analysed subjects, or be due to clusterin AD risk variant gene at rs11136000 locus (CLU rs11136000; [24, 25] ).
Higher levels of platelet tau protein (corresponding to both oligomeric and monomeric tau species as visualised on western blot) have been recently reported in AD [26] . Although our quantitative measures of both the microtubule- Gender did not influence the platelet protein expression; however, female AD subjects had a marginally elevated levels of α-synuclein [64. binding region and C-terminal end of tau protein were similar between AD and control subjects, we cannot exclude a possibility that AD platelet tau may undergo similar posttranslational modifications as tau protein incorporated in neurofibrillary pathology. In support of this are recent reports of higher platelet enzymatic GSK3-β activity in elderly subjects with MCI and AD [27] . Future work is now needed to address whether these tau protein changes are also present in the platelets of AD subjects. Our study has a few limitations, both in respect to clinical sampling and methodological design. Most of our AD subjects were highly educated, and highly functioning on cognitive tests. Out of a total of 25, 22 were treated with ChEIs, thus raising the possibility that the expression of platelet biomarkers may have been affected by the medication. Similarly, seven of the control subjects had lower MMSE scores (24-27/30 MMSE, with CAMCOG scores ranging from 84 to 101), but none of them fulfilled the NINCDS-ADRDA diagnostic criteria for AD. A longitudinal study of this cohort will be important to monitor the platelet changes in respect to cognitive performance over time.
Previous studies on CSF and blood derivates have largely used sandwich immunoassays that do not require an antigen purification step. The immunoassays we developed for the current study were based on relatively purified antigens, and had good intra-and inter-assay precision (<10%). The indirect ELISA assays we used enable analyses of various platelet proteins of interest, and have a potential to be expanded on the development of sandwich or multiplex immunoassays.
The analysed platelet proteins have relatively high sensitivity and specificity in comparison with previously described blood biomarkers, in particular, in relation to the inflammatory markers in plasma (α-2-macroglobulin and complement factor H [16] ). Further studies on larger number of AD subjects with various stages of cognitive impairment and other forms of dementia (e.g. VaD and Lewy Body dementias) will determine the usefulness of the identified platelet proteins for diagnosis of AD.
Key points
• Platelets contain dementia biomarkers, e.g. APP, tau protein and also α-synuclein, clusterin and Ig.
• Similar platelet levels of APP-N, tau, α-synuclein and clusterin were found in AD and control subjects.
• AD subjects had slightly elevated levels of platelet Ig (P = 0.052). This up-regulation was not related to increasing age, gender or extent of cognitive impairment in AD.
• Platelet APP-N measures were negatively correlated with CAMCOG and MMSE scores.
• Platelet measures of AD-associated proteins are feasible in the periphery, and merit further study in a larger cohort of AD and control subjects.
